Deal strengthens Henry Schein’s position in the growing home medical supply market.
Henry Schein (Nasdaq: HSIC) announced the completion of its acquisition of Acentus, a Tampa-based national supplier specializing in continuous glucose monitors (CGMs). This move reinforces Henry Schein’s strategic focus on the homecare medical supplies market, expanding its annual homecare platform revenue to over $350 million.
Key Highlights of the Acquisition
- Acentus Overview:
- Annual revenue of $35 million.
- Product categories include CGMs, urological catheters, wound care, and more.
- Impact on Henry Schein:
- Neutral impact on 2025 non-GAAP earnings per share, accretive thereafter.
- Strengthens ability to directly deliver CGM products to patients’ homes.
- Leadership Integration:
- Acentus founders Brett Carroll, Todd Cianfrocca, Greg Duvall, and Julio Valdivia join Henry Schein, bringing deep expertise in the health care industry.
Strategic Vision
Stanley M. Bergman, Chair and CEO of Henry Schein, emphasized the deal’s importance:
“This acquisition represents an important step in strengthening our position in the home medical supply market. By directly delivering CGM products to patients’ homes, we enhance our ability to serve customers and drive growth.”
Henry Schein continues to expand its national homecare solutions platform, addressing the needs of clinics, physician practices, health systems, and homecare patients.
Follow MEDWIRE.AI for more updates on acquisitions shaping the future of healthcare delivery.
